Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis
Arthritis & Rheumatology · 2026-02 · 78 (2) · 418-427
DOI: 10.1002/art.43370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.11.2025. Verfasst von Kimberly S Lakin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery, New York City, New York. Hauptthemen laut MEDLINE: Skin, Scleroderma, Diffuse, Actins, Fibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Scleroderma Foundation, Hospital for Special Surgery Research Institute Kellen Scholars Program.
Abstract (Originalsprache)
Objective
To evaluate the relationship of skin fibroblast CD34 and α‐smooth muscle actin (α‐SMA) and immune cell infiltration with disease duration in diffuse cutaneous systemic sclerosis (dcSSc) and identify predictors of improvement.
Methods
Skin biopsies and clinical data were analyzed from patients with dcSSc enrolled in lenabasum (n = 79), belimumab (n = 18), or nilotinib (n = 8) trials. CD34 and α‐SMA were scored semiquantitatively. Immune cells (CD20+, CD3+, and CD123+) were counted. Clinical and histologic features were compared between those with early (5‐point decrease in modified Rodnan skin score (mRSS) at 52 weeks. An Akaike's information criterion–optimal multiple logistic regression model for clinical improvement among 68 mycophenolate mofetil (MMF) users was developed. Fibroblast spatial organization was visualized using imaging mass cytometry (IMC) in a representative sample.
Results
Despite similar baseline mRSS, early disease was associated with lower CD34, higher α‐SMA, increased B cells, and greater mRSS improvement compared with later SSc. IMC demonstrated regions of CD34+ fibroblasts in superficial dermis and α‐SMA+ fibroblasts in deeper, collagen‐dense regions. Among MMF users, high CD34 and α‐SMA predicted improvement in early SSc; however, high α‐SMA predicted lower odds of improvement in later SSc. The probability of improvement was lowest in early SSc with α‐SMA low /CD34 low immunophenotype and later SSc with α‐SMA high . In later SSc, B cells were higher in α‐SMA high versus α‐SMA low skin.
Conclusion
Fibroblast immunophenotype varied by baseline disease duration and improved model performance for identifying those with improvement on MMF. Skin biopsies may be useful for refining prognosis and guiding patient management decisions. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital for Special Surgery, New York City, New York.
- Weill Cornell Medicine, New York City, New York.
- Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York City, New York.
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York City, New York.
- Department of Dermatology; Department of Microbiology and Immunology, Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, New York City, New York.
- Parker Institute for Cancer Immunotherapy and Sandra and Edward Meyer Cancer Center of Weill Cornell Medicine, New York City, New York.
ORCID-Profile: Jessica K Gordon, Deanna Jannat-Khah, Robert F Spiera
Förderung
- NIAMS NIH HHS
- National Scleroderma Foundation
- Hospital for Special Surgery Research Institute Kellen Scholars Program
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Lakin, K. S., Spivack, J., Gordon, J. K., Zhang, Y., Jannat-Khah, D., Ravichandran, H., Anandasabapathy, N., Orange, D. E., & Spiera, R. F. (2026). Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 78(2), 418-427. https://doi.org/10.1002/art.43370
Vancouver
Lakin KS, Spivack J, Gordon JK, Zhang Y, Jannat-Khah D, Ravichandran H, et al. Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 2026;78(2):418-427. doi:10.1002/art.43370
BibTeX
@article{Lakin2026,
author = {Lakin, Kimberly S and Spivack, John and Gordon, Jessica K and Zhang, Yaxia and Jannat-Khah, Deanna and Ravichandran, Hiranmayi and Anandasabapathy, Niroshana and Orange, Dana E and Spiera, Robert F},
title = {Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {2},
pages = {418--427},
doi = {10.1002/art.43370}
}
EUVIMED